Filing Flows › AstraZeneca (AZN) › Q2 2025
AstraZeneca (AZN) Q2 2025 earnings results (second quarter 2025)
6-K filed Jul 29, 2025
AstraZeneca (AZN) reported revenue of $14.5B for the second quarter 2025 (Q2 2025), +12% from a year earlier. Operating margin was 24.3%, net earnings $2.4B (16.9% of revenue).
AstraZeneca, Q2 2025: revenue $14.5B (+12% year over year), operating margin 24.3%, net earnings $2.4B. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.5B | — | +12% |
| Gross profit | $12.0B | — | +11% |
| Operating profit | $3.5B | — | +28% |
| Net earnings | $2.4B | — | +27% |
What changed
Revenue was $14.5B in Q2 2025, up 12% year over year. Product Revenue was the largest line at 100% of revenue.
Gross margin was 82.9%, down 0.2 points from a year earlier. Operating profit was $3.5B, a 24.3% margin (up 3.0 points year over year). Of the extra revenue versus a year earlier, 50% reached operating profit, above the 21% margin then. Operating expenses grew 6% against revenue growth of 12%. The fastest-growing cost line was Research & development (+18%). Net earnings were $2.4B, up 27% year over year. The effective tax rate was 21.7%.
Questions
What was AstraZeneca's revenue in the second quarter 2025?
AstraZeneca (AZN) reported revenue of $14.5B for the second quarter 2025 (Q2 2025), +12% from a year earlier.
Was AstraZeneca profitable in the second quarter 2025?
Operating profit was $3.5B (24.3% of revenue) and net earnings $2.4B.
Source: AstraZeneca 6-K on SEC EDGAR.